Stay updated on Nivolumab in Hodgkin Lymphoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.

Latest updates to the Nivolumab in Hodgkin Lymphoma Clinical Trial page
- Check2 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4. The study details and layout remain unchanged.SummaryDifference0.0%

- Check9 days agoNo Change Detected
- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAn administrative change was made: a new Revision: v3.3.3 was added and the HHS Vulnerability Disclosure and Revision: v3.3.2 were removed from the page footer. The study content, eligibility criteria, and outcomes remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check53 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no substantive changes to study details, eligibility criteria, or page navigation were observed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check60 days agoChange DetectedThe page no longer displays the government funding lapse notice and NIH Clinical Center operating status guidance. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check74 days agoChange DetectedThe core study details and eligibility criteria appear unchanged between the two screenshots; only minor UI formatting differences are visible.SummaryDifference0.3%

- Check103 days agoChange Detected- Added a government funding lapse notice with operating status guidance and a link to cc.nih.gov and opm.gov. - Updated version from v3.1.0 to v3.2.0.SummaryDifference4%

Stay in the know with updates to Nivolumab in Hodgkin Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab in Hodgkin Lymphoma Clinical Trial page.